Abstracts tagged "risk assessment"

Abstract Number: 0522 • ACR Convergence 2025
The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis
Abdulrahman Y Almansouri¹, Jiayi Li², Ali Alhadri³, Keith Colaco⁴, Paula Harvey⁵, Shadi Ahktari⁶, Vinod Chandran⁷, Dafna D. Gladman⁸, Richard Cook² and Lihi Eder⁷, ¹King Faisal Specialist Hospital and Research Centre, University of Toronto and Women's College Hospital, Toronto, Canada, ²University of Waterloo, Waterloo, Canada, ³King Fahad Hospital, University of Toronto and Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, Canada, ⁴University of Toronto, Toronto, Canada, ⁵University of Toronto Department of Medicine and Women's College Hospital, Toronto, ON, Canada, ⁶University of Toronto Department of Medicine and Women's College Hospital, Toronto, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk of developing cardiovascular diseases, including arrhythmias. Given that traditional cardiovascular disease risk factors are prevalent…
Abstract Number: 1658 • ACR Convergence 2025
Cardiovascular Disease Risk and Risk Calculator Performance in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Omair Khan¹, Halie Frideres², Punyasha Roul³, Grant Cannon⁴, Gary Kunkel⁵, Brian Sauer⁶, Joshua Baker⁷, Ted Mikuls¹, Bryant England¹ and Tate Johnson¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Existing cardiovascular disease (CVD) risk stratification strategies underperform in RA. Lung disease is an established CVD risk factor, and RA-interstitial lung disease (RA-ILD) clinically…
Abstract Number: 2249 • ACR Convergence 2025
Evaluation of a Screening Tool for Identifying Risk of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with Targeted Therapies
Marina Pavía-Pascual¹, Marina Sánchez-Lucas², Camille Bourgeois³, Maria Teresa Schiaffino Garcia-Villanova⁴, Julia Martínez Barrio⁵, Juan Molina-Collada⁶, Esther Chamorro De Vega⁷, José María álvaro-Gracia álvaro⁸ and Isabel Castrejón Fernández⁹, ¹Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ²Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain, ³Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, ⁴Department of Immunology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁵Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ⁶Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Spain, ⁷Pharmacy department, Hospital General Universitario Gregorio Marañón.Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁸Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. Department of Medicine, Complutense University, Madrid, Spain., Madrid, Madrid, Spain, ⁹MD, PhD, Madrid, Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is the second leading cause of mortality in rheumatoid arthritis (RA) but often goes underdiagnosed due to its variable clinical…
Abstract Number: 0786 • ACR Convergence 2025
A Machine Learning Approach to Understand Age as a Risk Factor for Complications After Total Hip Arthroplasty
Chloe Heiting¹, Yiyuan Wu², Susan Goodman³, Peter Sculco⁴, Fei Wang², Rich Caruana⁵, Peter Cram⁶, Said Ibrahim⁷ and Bella Mehta⁸, ¹Northwell Health, New Hyde Park, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵Microsoft, Redmond, WA, ⁶University of Maryland School of Medicine, Baltimore, MD, ⁷Thomas Jefferson University, Philadelphia, PA, ⁸Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Utilization of total hip arthroplasty (THA) has grown rapidly in the United States and worldwide. Postoperative complications and patient risk is of great consideration…
Abstract Number: 1749 • ACR Convergence 2025
External validation of a combined clinical and genetic risk score for the identification of interstitial lung disease in rheumatoid arthritis
Mikael Brink¹, Austin Wheeler², Bryant England² and Solbritt Rantapaa-Dahlqvist³, ¹Umeå Universitet, Umeå, Sweden, ²University of Nebraska Medical Center, Omaha, NE, ³Umeå University, Umea, Sweden
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) causes substantial morbidity and mortality in RA. Despite this, a limited number of clinical and genetic risk factors have…
Abstract Number: 2377 • ACR Convergence 2025
Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Aakash V. Patel¹, Lingxiao Zhang², Emily S. Lau³, Hyon K. Choi⁴ and April Jorge⁵, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Harvard Medical School, Boston, ⁴MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁵Massachusetts General Hospital, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of mortality among patients with systemic lupus erythematosus (SLE). Statin medications play a crucial role for…
Abstract Number: 0879 • ACR Convergence 2025
Trajectories and risk factors of interstitial lung disease in limited cutaneous systemic sclerosis from the EUSTAR cohort
Antonio Tonutti¹, Francesca Motta¹, Silvia Bellando Randone², Nicoletta Del Papa³, Elisabetta Zanatta⁴, Marie-Elise Truchetet⁵, Christina Bergmann⁶, Gábor Kumánovics⁷, Monique Hinchcliff⁸, Yasser El Miedany⁹, Britta Maurer¹⁰, Marie Vanthuyne¹¹, Lijun Zhang¹², Nune Manukyan¹³, Carlo Selmi¹⁴ and Maria De Santis¹, ¹Humanitas University, Pieve Emanuele, Italy, ²University of Florence, Florence, Italy, ³ASST Pini CTO, Milano, Milan, Italy, ⁴University of Padua, Padova, Italy, ⁵University of Bordeaux, Bordeaux, France, ⁶Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁷University of Pecs, Pecs, Hungary, ⁸Yale School of Medicine, Westport, CT, ⁹Egyptian Society for Microcirculation in Rheumatic Diseases, Cairo, Egypt, ¹⁰Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ¹¹Université Catholique de Louvain, Bruxelles, Belgium, ¹²The University of Hong Kong-Shenzhen Hospital, Shenzhen, China (People's Republic), ¹³Mikaelyan Institute Of Surgery, Yerevan, Armenia, ¹⁴Humanitas University, Milan, Italy
Background/Purpose: Interstitial lung disease (ILD) is traditionally associated with the diffuse subset of systemic sclerosis (dcSSc) but may be observed in limited SSc (lcSSc), with…
Abstract Number: 1911 • ACR Convergence 2025
Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort
Victoria Konzett¹, Eva Manger², Simon Reider², Johannes Griss³, Constanze Jonak³, Kastriot Kastrati⁴, Peter Mandl⁴, Gudrun Ratzinger⁵, Christina Duftner², Thomas Karonitsch⁴ and Daniel Aletaha⁶, ¹Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria, ³Department of Dermatology, Medical University of Vienna, Austria, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Austria, Innsbruck, Austria, ⁶Medical University Vienna, Wien, Austria
Background/Purpose: Psoriatic arthritis (PsA) develops predominantly in patients with psoriasis (Pso). Although key drivers and predictors of disease progression have been identified in recent years,…
Abstract Number: 2444 • ACR Convergence 2025
Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation
Emily Gutowski¹, Jessica Dai², Erin Carter³, Brooke Cohen⁴, Jill Buyon⁵, Chung-E Tseng⁶, Mala Masson⁷, Amit Saxena⁵, H Michael Belmont⁸, Joseph Colcombe⁶, Yasha Modi³, Carol Lee⁶ and Peter Izmirly⁹, ¹New York University Grossman School of Medicine, Brooklyn, NY, ²New York University Grossman School of Medicine, Tenafly, NJ, ³New York University Grossman School of Medicine, New York, NY, ⁴Yale Physician Associate Program, New Haven, CT, ⁵NYU Grossman School of Medicine, New York, NY, ⁶New York University Grossman School of Medicine, New York, ⁷NYU Langone Health, New York, ⁸NYU School of Medicine, New York, NY, ⁹New York University Grossman School of Medicine, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone of systemic lupus erythematosus (SLE) management, but long-term use carries the risk of retinopathy. While prior studies have identified…
Abstract Number: 0884 • ACR Convergence 2025
Risk Score for Early Mortality to stratify for Intensive SSc Therapy
Ann-Christin Pecher¹, Boubaya Marouane², Oliver Distler³, Vanessa Smith⁴, Jeska de Vries-Bouwstra⁵, Radim Bečvář⁶, Gianluca Moroncini⁷, David Launay⁸, Yannick Allanore⁹, Maria De Santis¹⁰, Kamal Solanki¹¹, Carlomaurizio Montecucco¹², Luca Idolazzi¹³, Nihal Fathi¹⁴, Przemyslaw Kotyla¹⁵, Muriel Elhai¹⁶ and Jörg Henes¹⁷, ¹Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany, ²Unit of Clinical Research, Paris Seine Saint Denis University, Bobigny, France, Paris, France, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁴Ghent University Hospital, Gent, Belgium, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Internal Medicine, Charles University,, Prague, Czech Republic, ⁷Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁸Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Département de Médecine interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille France, Lille, France, ⁹Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France, ¹⁰Humanitas University, Pieve Emanuele, Italy, ¹¹Waikato Hospital, Hamilton, New Zealand, ¹²Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, Pavia, Italy, ¹³Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy, Verona, Italy, ¹⁴Department of Rheumatology ,Rehabilitation & physical medicine, Assiut University Hospital, Assiut, Egypt, Assiut, Egypt, ¹⁵Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical University of Silesia, Katowice, Poland, ¹⁶University Hospital zurich, Zürich, Switzerland, ¹⁷Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany
Background/Purpose: Systemic sclerosis (SSc) is a rare disease that often leads to severe complications and premature mortality. Recent advancements in the field have led to…
Abstract Number: 1912 • ACR Convergence 2025
Cutaneous manifestations of vasculitis: A cross-sectional analysis from an international cohort
Robert Micheletti¹, William Song¹, Brian Chu², Lynne Allen-Taylor³, Joel Gelfand³, Peter Grayson⁴, Cristina Ponte⁵, Joanna Robson⁶, Ravi Suppiah⁷, Raashid Luqmani⁸, Richard Watts⁹ and Peter Merkel¹⁰, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Brown University Health, Providence, RI, ³University of Pennsylvania, Philadelphia, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁵Unidade Local de Saúde de Santa Maria, Lisbon, Portugal, ⁶University of the West of England Bristol, Bristol, United Kingdom, ⁷Health New Zealand - Te Toka Tumai, Auckland, New Zealand, ⁸University of Oxford, Oxford, United Kingdom, ⁹University of East Anglia, Norwich, United Kingdom, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: Vasculitis is a group of rare, multisystem diseases which may involve the skin. Characterization of the frequency, type, and significance of cutaneous manifestations in…
Abstract Number: 2473 • ACR Convergence 2025
Nailfold Capillaroscopy Improves Cardiovascular Risk Stratification in Systemic Sclerosis: An Adjustment to the SCORE2 Algorithm
Carlos Valera Ribera¹, Javier Narváez², Joaquin Lacasa Molina³, Adrián Mayo-Juanatey⁴, Paula Mencio⁵, Patricia Leon Torralba⁵, Pablo Andujar Brazal⁵, Ignacio Vázquez Gómez⁶ and JUAN JOSE ALEGRE SANCHO⁷, ¹Hospital Universitario Doctor Peset, València, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ⁵Hospital Universitario Doctor Peset, València, Comunidad Valenciana, Spain, ⁶H.U. Doctor Peset, Valencia, ⁷Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain
Background/Purpose: Systemic sclerosis (SSc) is associated with both micro- and macrovascular damage, increasing cardiovascular (CV) risk. The SCORE2 algorithm estimates CV event risk in the…
Abstract Number: 0203 • ACR Convergence 2025
Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study
Sung Ik Cho¹, Jin Kyun Park², Hee Won Cho³, Eun Young Lee⁴, Eun Bong Lee¹ and Jun Won Park¹, ¹Seoul National University Hospital, Seoul, South Korea, ²Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea, ³Seoul National University, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁴Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: Cytomegalovirus (CMV) infection is a well-recognized complication in immunocompromised individuals, yet there islimited evidence guiding surveillance strategies in patients with rheumatic diseases on immunosuppressants.…
Abstract Number: 0614 • ACR Convergence 2025
Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound
Ileana C. Reynosa-Silva¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Aleydis Gonzalez-Melendez¹, Iris J. Colunga-Pedraza³, Dionicio A. Galarza-Delgado³, Jose R Azpiri-Lopez⁴, Rosa Arvizu-Rivera⁵, Jesus Alberto Cardenas-de la Garza⁶ and Diego Azamat Salcedo Almanza⁷, ¹Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with an elevated risk of cardiovascular (CV) disease, largely due to chronic inflammation and…
Abstract Number: 1937 • ACR Convergence 2025
Does Combining Standard MRI-Based Scores with Radiographic Trabecular Bone Texture Biomarkers Improve Predictive Performance for Radiographic Knee Osteoarthritis Progression?
Ahmad Almhdie-Imjabbar¹, Saida Daroussi², Daniela Herrera³, Hechmi Toumi² and Eric Lespessailles⁴, ¹University Hospital Center of Orleans, Orleans, France, ²PRIMMO- University Hospital Center of Orleans, Orleans, France, ³PRIMMO- University Hospital Center of Orleans, Olreans, France, ⁴CHU Orléans, Orléans, France
Background/Purpose: Knee osteoarthritis (KOA) is a major cause of disability worldwide, particularly impacting the elderly and obese population. Radiographic trabecular bone texture (TBT) is demonstrated…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].